Go To Global Site
Welcome to UCB in the United States

Nov

17

UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Nov

12

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Nov

05

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Oct

31

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients

Oct

29

UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology

1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Sep

22

UCB Achieves Important Regulatory Milestone for Bimekizumab

  • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
  • This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16
1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Sep

14

Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

•    Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration 

Aug

31

Press Release: Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry

  • Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo 

Jul

29

Press Release: UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease

UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease

Jul

24

Press Release: Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance

Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance